Eyal Attar, MD

Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as senior vice president and CMO for Aprea Therapeutics where he led development […]

Read More… from Eyal Attar, MD

Veit Schmelmer, PhD

Veit Schmelmer, PhD oversees the management of Vor Bio’s clinical research programs, working with cross-functional teams and external collaborators to advance the company’s engineered Hematopoietic Stem Cell (eHSC) platform. Veit has over 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders, and infectious diseases at leading biopharmaceutical companies. Most recently, […]

Read More… from Veit Schmelmer, PhD

Robert Pietrusko, PharmD

Bob Pietrusko, PharmD has directed the worldwide approval of more than 30 new products. He also led the submission and approval strategies for more than 30 new drug applications (NDAs), supplemental NDAs, biologics license applications, and marketing authorization applications in multiple therapeutic areas. As an early team member at Voyager Therapeutics, Bob pioneered regulatory strategies […]

Read More… from Robert Pietrusko, PharmD

Tania Philipp

Tania Philipp, Chief People Officer, brings more than 15 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company […]

Read More… from Tania Philipp

Tirtha Chakraborty, PhD

Tirtha Chakraborty, PhD brings expertise in both hematology and genetic engineering to his role as Chief Scientific Officer. He formerly served as Vor Bio’s Vice President and Head of Research. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology […]

Read More… from Tirtha Chakraborty, PhD

John King, MBA

John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global […]

Read More… from John King, MBA

Nathan Jorgensen, PhD, MBA

Nathan Jorgensen PhD, MBA brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his role at Vor Bio. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, he led investments […]

Read More… from Nathan Jorgensen, PhD, MBA

Robert Ang

Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he […]

Read More… from Robert Ang